Recordati S.a. Chemical and Pharmaceutical Company

Pharmaceutical Company

Recordati S.a. Chemical

Giorgio Sironi

Amedeo Leonardi

Gianni Motta

Rodolfo Testa

Carlo Riva

Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the &#x3b1;-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.

Use of selective antagonists of the &#x3b1;1B-adrenergic receptor for improvement of sexual dysfunction

The invention relates to novel benzopyran derivatives of formula I, their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS), neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.

Benzopyran derivatives

Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the &agr;,-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.

Growing community of inventors

Pieve Emanuele, Italy

Giorgio Sironi